Patients with autoimmune diseases who take GLP-1 receptor agonist drugs appear to face a lower risk of death and blood clots than those who do not, according to a report by U.S. News and World Report.
GLP-1 receptor agonists are a class of drugs that were originally developed to treat type 2 diabetes and obesity. Medications in this class include semaglutide, sold under brand names such as Ozempic and Wegovy, and have become widely prescribed in recent years. The new findings suggest their benefits may extend to patients managing autoimmune conditions.
The study adds to a growing body of research examining what GLP-1 drugs do beyond controlling blood sugar and body weight. Researchers have been looking at whether these medications affect inflammation, the immune system, and the cardiovascular system in ways that might help patients with diseases like lupus, rheumatoid arthritis, and multiple sclerosis.
Autoimmune diseases occur when the immune system mistakenly attacks the body's own tissues. Many of these conditions are already associated with higher risks of cardiovascular disease, blood clots, and early death, which makes the potential protective effects of GLP-1 drugs particularly relevant for this patient population.
The findings do not establish that GLP-1 drugs cause the lower rates of death and clotting. Patients who take these medications may differ in other ways from those who do not, including in their overall health status, access to care, or other treatments they receive. Researchers typically account for some of these differences, but observational studies of this kind carry limitations.
Physicians who treat autoimmune patients have been watching this line of research closely. Many of their patients carry elevated cardiovascular risk as a direct consequence of chronic inflammation, and any intervention that reduces that risk is of significant clinical interest.
The study does not appear to recommend that autoimmune patients seek out GLP-1 drugs specifically for clot or mortality prevention. Patients with autoimmune conditions who have questions about these medications should speak with their doctors about whether they are appropriate given their individual circumstances.
